Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC.

Cancer Res. 2009 Mar 1;69(5):1722-7. doi: 10.1158/0008-5472.CAN-08-3933. Epub 2009 Feb 24.

2.

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Hoskins JM, Carey LA, McLeod HL.

Nat Rev Cancer. 2009 Aug;9(8):576-86. doi: 10.1038/nrc2683. Review.

PMID:
19629072
3.

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.

J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. Review.

PMID:
19200418
4.

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

Briest S, Stearns V.

Clin Adv Hematol Oncol. 2009 Mar;7(3):185-92. Review.

PMID:
19398943
5.

Estrogen receptors as therapeutic targets in breast cancer.

Ariazi EA, Ariazi JL, Cordera F, Jordan VC.

Curr Top Med Chem. 2006;6(3):181-202. Review.

PMID:
16515478
6.

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.

Higgins MJ, Stearns V.

Curr Oncol Rep. 2010 Jan;12(1):7-15. doi: 10.1007/s11912-009-0076-5. Review.

PMID:
20425602
7.

Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

Brauch H, Jordan VC.

Eur J Cancer. 2009 Sep;45(13):2274-83. doi: 10.1016/j.ejca.2009.05.032. Epub 2009 Jul 9. Review.

PMID:
19592233
8.

EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.

Labrie F, Labrie C, Bélanger A, Simard J, Giguère V, Tremblay A, Tremblay G.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):213-25. Review.

PMID:
11850228
9.

Tamoxifen and CYP2D6: a contradiction of data.

Hertz DL, McLeod HL, Irvin WJ Jr.

Oncologist. 2012;17(5):620-30. doi: 10.1634/theoncologist.2011-0418. Epub 2012 Apr 24. Review.

10.

Pharmacogenetics of anti-estrogen treatment of breast cancer.

Del Re M, Michelucci A, Simi P, Danesi R.

Cancer Treat Rev. 2012 Aug;38(5):442-50. doi: 10.1016/j.ctrv.2011.08.003. Epub 2011 Sep 13. Review.

PMID:
21917382
11.

Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.

Binkhorst L, Mathijssen RH, Jager A, van Gelder T.

Cancer Treat Rev. 2015 Mar;41(3):289-99. doi: 10.1016/j.ctrv.2015.01.002. Epub 2015 Jan 14. Review.

PMID:
25618289
12.

Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.

Yang G, Nowsheen S, Aziz K, Georgakilas AG.

Pharmacol Ther. 2013 Sep;139(3):392-404. doi: 10.1016/j.pharmthera.2013.05.005. Epub 2013 May 24. Review.

PMID:
23711794
13.

Coprescription of tamoxifen and medications that inhibit CYP2D6.

Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP.

J Clin Oncol. 2010 Jun 1;28(16):2768-76. doi: 10.1200/JCO.2009.23.8931. Epub 2010 May 3. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

14.

Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment.

Walko CM, McLeod H.

Pharmacogenomics. 2012 Apr;13(6):691-7. doi: 10.2217/pgs.12.27. Review.

PMID:
22515611
15.

Individualization of tamoxifen treatment for breast carcinoma.

Binkhorst L, van Gelder T, Mathijssen RH.

Clin Pharmacol Ther. 2012 Oct;92(4):431-3. doi: 10.1038/clpt.2012.94. Epub 2012 Aug 22. Review.

PMID:
22910442
16.

The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer.

Spears M, Bartlett J.

Expert Opin Ther Targets. 2009 Jun;13(6):665-74. doi: 10.1517/14728220902911509. Review.

PMID:
19456271
17.

Pharmacogenomics of endocrine therapy in breast cancer.

Weinshilboum R.

Adv Exp Med Biol. 2008;630:220-31. Review.

PMID:
18637494
18.

Rethinking tamoxifen in the management of melanoma: New answers for an old question.

Ribeiro MP, Santos AE, Custódio JB.

Eur J Pharmacol. 2015 Oct 5;764:372-8. doi: 10.1016/j.ejphar.2015.07.023. Epub 2015 Jul 9. Review.

PMID:
26165763
19.

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H.

Clin Cancer Res. 2009 Jan 1;15(1):15-21. doi: 10.1158/1078-0432.CCR-08-2006. Review.

20.

[Antagonism of tamoxifen and antidepressants among women with breast cancer].

Irarrázaval O ME.

Rev Med Chil. 2011 Jan;139(1):89-99. doi: /S0034-98872011000100013. Epub 2011 Apr 11. Review. Spanish.

Items per page

Supplemental Content

Write to the Help Desk